Vipul Parekh

Our team spent months working out the right pod size for this frozen pea, measuring it down to the millimetre. And yet, the zip-lock slider bag it comes in that took a day to design, has become as popular as the matar itself. I've been told that hundreds of people have written in about how they're happily reusing the bag for storing dry fruits and other pantry items. Something that none of us thought would impress so many. A reminder that the customer always knows something about your product that you don't... which is what makes them the most valuable people in your business. 😄 @bigbasket_com #bigbasket #fresho #privatelabels

Let me explain exactly why Apple still uses drag-to-install in 2026, because the joke here accidentally proves Apple right. A macOS .app is a single self-contained folder disguised as a file. Every dependency, every framework, every resource lives inside it. Drag it to Applications, it works. Drag it to Trash, it's gone. No registry entries. No leftover DLLs. No uninstaller that misses half the files. Windows installers scatter fragments across Program Files, AppData, the registry, system32, and a dozen temp directories. Uninstalling a Windows app is an archaeological dig. Five years later you're still finding config files from software you forgot you owned. Linux is worse. Dependency hell is so common they named it. Entire package managers exist to solve the problem of "I installed something and now nothing else works." Flatpak and Snap were invented specifically to copy what macOS bundles already did natively. The macOS bundle architecture came from NeXTSTEP in 1989. Steve Jobs brought it to OS X in 2001. The core design hasn't changed because the core design was correct. An app is a folder. Installation is a copy. Removal is a delete. Three operations that map perfectly to how humans already think about files. The drag-to-install window with the arrow isn't lazy UX. It's the entire thesis of the system made visible. You are literally just moving a folder. There is no "installation" step because there's nothing to install. The app is already complete. Every other OS eventually tried to get here. Windows got MSIX. Linux got Flatpak. Mobile figured it out from day one because phones shipped after Apple proved the model. The pattern everyone else converged toward is the pattern this tweet is calling outdated. The funniest part: the app being dragged in that screenshot is Claude. An AI that can write code, analyze documents, and reason about complex systems. And the most advanced step in getting it onto your machine is holding down a mouse button and moving your wrist two inches to the right. That's not a design failure. That's a 37-year-old architecture so good that the most sophisticated software on earth still ships inside it.

Today in @NatureMedicine we report that AI can predict 130 diseases from 1 night of sleep🛌 We trained a foundation model (#SleepFM) on 585K hours of sleep recordings from 65K people—brain, heart, muscle & breathing signals combined. AI learns the language of sleep🧵

This man who grew up in middle class India literally built the only startup outside US/China/Japan that sent rockets to space. Here's the never-before-shared crazy story of Pawan Chandana: > be middle class kid growing up in Vizag > terrible student, get 51 marks in maths > ambitious dad doesn't give up, puts you in IIT coaching > fall in love with math and science > go from worst to best in school > crack IIT first attempt > 2007: go to IIT KGP for mechanical engineering > everyone around you chasing big packages, consulting, going abroad > you just love rockets > 2012: join ISRO as scientist straight out of campus > pays peanuts > loves it > doing so well you want to retire here > but entrepreneurial bug from IIT days never left > dreams of building a global space company from India > but no policy allowing private rockets, no funding environment for space > 2018: quit anyway, ready to survive in rags > googles "what is equity" > zero connections > cold DM Mukesh Bansal on LinkedIn > he writes a $1.5M check > COVID hits, seed capital running out > Series A is a brutal struggle > no fund invests > founders of renewable company Greenko invests > 2021: PM Modi opens up space sector to private players > become first company to sign MoU with ISRO > get largest check in Indian DeepTech, $51M > Nov 18, 2022: launch Vikram-S: India's first suborbital private rocket > reaches 90km > Prime Minister Modi inaugurates your new facility > grow to 1000 employees > build India's largest private rocket factory at 200,000 sq ft > valued at $527M > first orbital launch, Vikram-1, planned in 2026 > will be one of ~5 companies globally regularly launching to orbit > next: reusable spaceships > Open Space for All We talk a lot about Elon Musk and SpaceX, but imagine having NO prior wealth. Being in a developing country. Constantly saying no to money. Being unable to raise any venture funding multiple times. Being called crazy by everyone. And still having the perseverance to dream beyond the stars. I'd call Pawan's story inspirational, but honestly it's more than that. It's beyond what I can fathom.

It's time to remove laptops from classrooms. 24 experiments: Students learn more and get better grades after taking notes by hand than typing. It's not just because they're less distracted—writing enables deeper processing and more images. The pen is mightier than the keyboard.

When Jemimah Rodrigues scored the brilliant 100 in semis yesterday, her demeanour reminded me of Virat Kohli, though every bit of it was her own. The way she played, calm & grounded without any over-celebration or self-pats. That’s something we often forget in the noise of personal milestones... that the big wins are rarely personal. She never talked about her score, she spoke about India’s win. The emotion of victory, she called it. And I strongly believe that’s what true leadership looks like... shared spirit. 🔥 🏏 She exuded the same steadiness when we worked with her earlier this year, you’ll see a glimpse of it in this little moment from our bigbasket shoot. 😊 #JemimahRodrigues #Bigbasket

gradCapital: Announcing an offer to fund students in India. $200k for 10%: if you want to work on your idea full-time. $60k for 5%: if there's time before you graduate, but still want to work on your idea. $2.5k grant: you want to work just on a project.

@ashishdave Woah! That’s some serious explosive potential😊

Raja Ramchandra ki Jai !! Happy Crackerwali Diwali 2025 !!

Fiverr CEO says “ AI is coming for your jobs. Heck, it’s coming for my job too.”

I for one am grateful Indian college admissions are determined through standardized tests. Though far from perfect, these tests are one of the few avenues for social advancement and prevent a total takeover of opportunity by the elite.

"Marketing is 10x harder than coding"

Larry Ellison: “Give me human will and the intense desire to win and it will trump talent every day of the week.”

The most expensive thing you’ll ever pay for is not what you think:

Preach

Western Biotech’s “DeepSeek Moment” – China’s Rise in Pharma Innovation The WSJ article opens with how Summit Therapeutics’ cancer drug, licensed from China’s Akeso, outperformed Merck’s $30B Keytruda. But apparently this isn't all that special — Chinese companies now account for 31% of major pharma licensing deals, up from just 5% in 2020. How Did China Get Here? The investment bank Stifel listed the below provocative answers they think you'd hear if you asked Chinese biotech CEOs. (Some of these answers seem like they apply to multiple industries, especially #1 & 2.) 1️⃣ You didn't appreciate us. "We worked in your American labs, but you wouldn’t promote us. So we went back to China and built our own companies. Now that you see how good we are, don’t complain." 2️⃣ We run lean and fast. "Your biotechs are bloated with unnecessary FTEs, fancy executive suites, and endless meetings. We focus on innovation, not bureaucracy. You’re paying for overhead, not breakthroughs." OUCH?! 3️⃣ We don’t need to steal your secrets. "Finding novel epitopes and mastering phage display isn’t rocket science. We innovate just like you—except we work harder." 4️⃣ You pushed Wuxi out—we welcomed them back. "You decided Wuxi Biologics was a threat. Fine. Now they focus on our molecules, working faster at a fraction of the cost. Again, don't complain." Why Chinese Biotech Is Winning ✅ Lower costs & streamlined clinical trials ✅ Lean operations with minimal bureaucracy ✅ Better drug candidates at lower prices ✅ Faster R&D with Wuxi and other CDMOs driving efficiency Global Pharma’s Growing Dependence on China - Nearly a third of licensed molecules in 2023-2024 came from China. - VEGF x PD-1, a major oncology breakthrough for solid tumors, originated in China, where research remains ahead of Western counterparts. - China is rapidly advancing first-in-class biologics and fundamental life sciences research. Finally, efforts to cut off China (e.g., BioSecure Act) are losing momentum, as they offer little national security benefit. What This Means for Western VC & Biotech Chinese biotech isn’t just competing—it’s delivering better drugs at lower prices. If this trend continues, industry experts are predicting it could disrupt the U.S. biotech funding model, as VCs struggle to justify sky-high valuations when superior alternatives are available for less. Meanwhile, India is also entering the game, adding to the competition. I’m no biotech expert, but after loosely following the industry for the past two years, this WSJ headline doesn’t surprise me. A decade ago, when LPs asked me to look into China’s then-nonexistent biotech sector, I never could have predicted its rapid rise. What’s more surprising—and disappointing—is seeing the U.S., once the gold standard for efficiency, now bogged down in the kind of bureaucracy I used to associate with China. But as a consumer, I’m excited to see China, India, and others join the race for better drugs. Links below in comments.

Flipkart Group -- which includes Myntra -- controls a 48% market share of India's online commerce.